A detailed history of Rafferty Asset Management, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 155,786 shares of ALT stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
155,786
Previous 221,591 29.7%
Holding current value
$1.35 Million
Previous $1.47 Million 35.1%
% of portfolio
0.0%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$5.5 - $8.1 $361,927 - $533,020
-65,805 Reduced 29.7%
155,786 $956,000
Q2 2024

Aug 13, 2024

SELL
$5.91 - $10.23 $3.91 Million - $6.76 Million
-661,037 Reduced 74.89%
221,591 $1.47 Million
Q1 2024

May 13, 2024

BUY
$8.22 - $13.81 $7.26 Million - $12.2 Million
882,628 New
882,628 $8.99 Million
Q1 2023

May 11, 2023

SELL
$4.19 - $16.83 $344,937 - $1.39 Million
-82,324 Reduced 13.75%
516,563 $2.18 Million
Q4 2022

Feb 13, 2023

BUY
$8.74 - $16.45 $2.61 Million - $4.91 Million
298,556 Added 99.41%
598,887 $9.85 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $3.2 Million - $6.73 Million
300,331 New
300,331 $3.84 Million
Q1 2022

May 13, 2022

SELL
$5.9 - $9.45 $2.14 Million - $3.43 Million
-362,943 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$8.69 - $12.48 $1.73 Million - $2.48 Million
198,865 Added 121.2%
362,943 $3.33 Million
Q3 2021

Nov 10, 2021

SELL
$8.43 - $16.81 $147,052 - $293,233
-17,444 Reduced 9.61%
164,078 $1.86 Million
Q2 2021

Aug 10, 2021

SELL
$9.85 - $16.46 $170,168 - $284,362
-17,276 Reduced 8.69%
181,522 $1.79 Million
Q1 2021

May 10, 2021

BUY
$12.71 - $24.31 $2.53 Million - $4.83 Million
198,798 New
198,798 $2.81 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $426M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.